Beatrice Nolan


Beatrice Nolan

Dr. Beatrice Nolan leads the multidisciplinary team at the Comprehensive Care Centre in Children’s Health Ireland at Crumlin, Dublin. Dr. Nolan was appointed as a Consultant Haematologist to St. James’s Hospital in 2001. In 2008 she was then appointed Lead Consultant Haematologist for paediatric haemophilia and allied bleeding disorders at Children’s Health Ireland at Crumlin with a national remit. She is a member of the National Haemophilia Council and the Haemophilia Product Selection and Monitoring Advisory Board.

Beatrice Nolan

Kasia Fennell PhD
Position: Senior Clinical Research Coordinator

Role:
Kasia works with the Haemostasis & Thrombosis Clinical Research team led by Consultant Haematologist Dr. Beatrice Nolan at Children’s Health Ireland at Crumlin.

Róisín Bradley
Position: Clinical Nurse Manager II Children’s Clinical Research Unit
roisin.bradley@olchc.ie

Antje Trainor
Position: Research Nurse

Aileen Molloy
Position: Research Nurse

The list of publications below is automatically derived from MEDLINE/PubMed. As a result, there may be incorrect or missing publications.

Carcao M, Escuriola-Ettingshausen C, Santagostino E, Oldenburg J, Liesner R, Nolan B, Bátorová A, Haya S, Young G, Future of Immunotolerance Treatment Group., 2019 Jul, The changing face of immune tolerance induction in haemophilia A with the advent of emicizumab. Haemophilia, DOI: 10.1111/hae.13762
Andersson NG, Auerswald G, Barnes C, Carcao M, Dunn AL, Fijnvandraat K, Hoffmann M, Kavakli K, Kenet G, Kobelt R, Kurnik K, Liesner R, Mäkipernaa A, Manco-Johnson MJ, Mancuso ME, Molinari AC, Nolan B, Perez Garrido R, Petrini P, Platokouki HE, Shapiro AD, Wu R, Ljung R, 2017 Oct, Intracranial haemorrhage in children and adolescents with severe haemophilia A or B - the impact of prophylactic treatment. Br J Haematol, DOI: 10.1111/bjh.14844
Fischer K, Kulkarni R, Nolan B, Mahlangu J, Rangarajan S, Gambino G, Diao L, Ramirez-Santiago A, Pierce GF, Allen G, 2017 Feb, Recombinant factor IX Fc fusion protein in children with haemophilia B (Kids B-LONG): results from a multicentre, non-randomised phase 3 study. Lancet Haematol, DOI: 10.1016/S2352-3026(16)30193-4
Pasi KJ, Fischer K, Ragni M, Nolan B, Perry DJ, Kulkarni R, Ozelo M, Mahlangu J, Shapiro AD, Baker RI, Bennett CM, Barnes C, Oldenburg J, Matsushita T, Yuan H, Ramirez-Santiago A, Pierce GF, Allen G, Mei B, 2017 Feb 28, Long-term safety and efficacy of extended-interval prophylaxis with recombinant factor IX Fc fusion protein (rFIXFc) in subjects with haemophilia B. Thromb Haemost, DOI: 10.1160/TH16-05-0398
Nolan B, Mahlangu J, Perry D, Young G, Liesner R, Konkle B, Rangarajan S, Brown S, Hanabusa H, Pasi KJ, Pabinger I, Jackson S, Cristiano LM, Li X, Pierce GF, Allen G, 2016 Jan, Long-term safety and efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) in subjects with haemophilia A. Haemophilia, DOI: 10.1111/hae.12766
Young G, Mahlangu J, Kulkarni R, Nolan B, Liesner R, Pasi J, Barnes C, Neelakantan S, Gambino G, Cristiano LM, Pierce GF, Allen G, 2015 Jun, Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A. J Thromb Haemost, DOI: 10.1111/jth.12911
Nijdam A, Kurnik K, Liesner R, Ljung R, Nolan B, Petrini P, Fischer K, PedNet study group., 2015 Jul, How to achieve full prophylaxis in young boys with severe haemophilia A: different regimens and their effect on early bleeding and venous access. Haemophilia, DOI: 10.1111/hae.12613
Nijdam A, Altisent C, Carcao MD, Cid AR, Claeyssens-Donadel S, Kurnik K, Ljung R, Nolan B, Petrini P, Platokouki H, Rafowicz A, Thomas AE, Fischer K, PedNet and CANAL study groups., 2015 Mar, Bleeding before prophylaxis in severe hemophilia: paradigm shift over two decades. Haematologica, DOI: 10.3324/haematol.2014.115709
Nabialek T, Pinnamaneni R, Saleemi MS, Nolan B, Corcoran JD, 2014 Sep, Intra-hepatic haemorrhage and shock during post-natal period, in two brothers with haemophilia. Ir Med J, DOI: 10.3324/haematol.2014.115709
Gouw SC, van den Berg HM, Fischer K, Auerswald G, Carcao M, Chalmers E, Chambost H, Kurnik K, Liesner R, Petrini P, Platokouki H, Altisent C, Oldenburg J, Nolan B, Garrido RP, Mancuso ME, Rafowicz A, Williams M, Clausen N, Middelburg RA, Ljung R, van der Bom JG, PedNet and Research of Determinants of INhibitor development (RODIN) Study Group., 2013 May 16, Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study. Blood, DOI: 10.1182/blood-2012-09-457036
Bacon CL, Singleton E, Brady B, White B, Nolan B, Gilmore RM, Ryan C, Keohane C, Jenkins PV, O'Donnell JS, 2011 May, Low risk of inhibitor formation in haemophilia A patients following en masse switch in treatment to a third generation full length plasma and albumin-free recombinant factor VIII product (ADVATE®). Haemophilia, DOI: 10.1111/j.1365-2516.2010.02430.x
Jenkins PV, Egan H, Keenan C, O'Shea E, Smith OP, Nolan B, White B, O'Donnell J, 2008 Jul, Mutation analysis of haemophilia B in the Irish population: increased prevalence caused by founder effect. Haemophilia, DOI: 10.1111/j.1365-2516.2008.01765.x
Singleton E, Smith J, Kavanagh M, Nolan B, White B, 2007 Dec, Low risk of inhibitor formation in haemophilia patients after a change in treatment from Chinese hamster ovary cell-produced to baby hamster kidney cell-produced recombinant factor VIII. Thromb Haemost, DOI: 10.1111/j.1365-2516.2008.01765.x
Nolan B, Vidler V, Vora A, Makris M, 2003 Jan 18, Unsuspected haemophilia in children with a single swollen joint. BMJ, DOI: 10.1136/bmj.326.7381.151
Nolan B, White B, Smith J, O'Reily C, Fitzpatrick B, Smith OP, 2000 Jun, Desmopressin: therapeutic limitations in children and adults with inherited coagulation disorders. Br J Haematol, DOI: 10.1046/j.1365-2141.2000.02067.x

Current Trials & Studies

Study NameStudy TitleStudy TypeSponsorSponsor Type
LoVIC-KLow Von Willebrand Factor in Ireland Kids Cohort StudyNon-interventional StudyRSCI, HRBAcademic - Collaborative Group
iPATHAn Irish Personalised Approach to the Treatment of HaemophiliaNon-interventional StudyRCSI, Shire, SFIIndustry Supported
LTE-15174ATLAS-OLE: An Open-label, Long-term Safety and Efficacy Study of Fitusiran in Patients with Hemophilia A or B, with or without Inhibitory Antibodies to Factor VIII or IXClinical Trial of IMPGenzyme CorporationIndustry supported
ALN-AT3SC-009A Phase 3 study to describe the efficacy and safety of Fitusiran prophylaxis in hemophilia A and B patients previously receiving factor or bypassing agent prophylaxis.Clinical Trial of IMPSanofi GenzymeIndustry supported
Elocta-003 ITI StudyA Non-Controlled, Open-Label, Multicenter, Study of Immune Tolerance Induction Performed with rFVIIIFc within a Timeframe of 60 Weeks in Severe Haemophilia A Patients with Inhibitors who have Failed Previous Immune Tolerance Induction TherapiesClinical Trial of IMPSobi (Swedish Orphan Biovitrum AB)Industry Sponsored
998HB303 (PUPS B)An Open Label Study to Determine the Safety and Efficacy of Replacement Factor VIII Protein (Known as rFVIIIFc) in Untreated Males With Severe Hemophilia AClinical TrialBioverativ A Sanofi CompanyIndustry Sponsored
997HA306 (PUPS A)An Open Label Study to Determine the Safety and Efficacy of Replacement Factor VIII Protein (Known as rFVIIIFc) in Untreated Males With Severe Hemophilia AClinical TrialBioverativ A Sanofi CompanyIndustry Sponsored
GAPPGenotyping and Phenotyping of PlateletsNon-Interventional StudyUniversity of BirminghamAcademic - Collaborative Group
PedNETThe European Paediatric Network for Haemophilia Management and the PedNet Haemophilia RegistryNon-Interventional StudyEuropean Paediatric Network for HaemophiliaAcademic - Collaborative Group

Previous Trials & Studies

Study NameStudy TitleStudy TypeSponsorSponsor Type
9HB01EXT (BYOND)Long-Term Safety and Efficacy of rFIXFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia B (B-YOND)Clinical TrialBioverativIndustry Sponsored
Einstein Junior Phase III – 14372BAY 59-7939/14372: Multicenter, open-label, active-controlled, randomized study to evaluate the efficacy and safety of an age-and body weight-adjusted rivaroxaban regimen compared to standard of care in children with acute venous thromboembolismClinical TrialBayer HealthCare AGIndustry Sponsored
LeopoldA multi-center Phase III uncontrolled open-label trial to evaluate safety and efficacy of BAY 81-8973 in children with severe haemophilia A under prophylaxis therapyClinical TrialBayer HealthCare AGIndustry Sponsored
Affinity CSL627_3001A Phase III Open-label, Multicenter, Extension Study to Assess the Safety and Efficacy of Recombinant Coagulation Factor VIII (rVIII-SinglChain, CSL627) in Subjects with Severe Hemophilia AClinical TrialCSL BehringIndustry Sponsored
8HA02PED (Kids A-LONG)Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Recombinant Coagulation Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Pediatric Subjects With Hemophilia AClinical TrialBiogenIndustry Sponsored
9HB02PED (Kids B-LONG)Study of Recombinant Coagulation Factor IX Fc Fusion Protein, BIIB029, in Previously Treated Pediatric Participants With Hemophilia BClinical TrialBiogenIndustry Sponsored
8HA01EXT (ASPIRE)Long-Term Safety and Efficacy of rFVIIIFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia AClinical TrialBiogenIndustry Sponsored
CSLCT-BIO-12-83An Open-label, Multi-centre Post-marketing Study to Assess the Efficacy and Safety of Voncento® in Subjects with Von Willebrand DiseaseClinical TrialCSL BehringIndustry Sponsored
Einstein Junior Phase III – 12892Phase I: Single-dose pilot study of oral rivaroxaban in pediatric subjects with venous thromboembolismClinical TrialBayer HealthCare AGIndustry Sponsored
Einstein Junior Phase I – 17992Single-dose study of oral rivaroxaban dry powder suspension formulation in children treated for thrombosisClinical TrialBayer HealthCare AGIndustry Sponsored